180 Life Sciences Corp.

AI Score

0

Unlock

1.58
0.00 (0.00%)
At close: Jan 17, 2025, 3:59 PM
1.54
-2.53%
After-hours Jan 17, 2025, 04:37 PM EST

Company Description

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.

Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

The company was incorporated in 2016 and is headquartered in Palo Alto, California.

180 Life Sciences Corp.
180 Life Sciences Corp. logo
Country United States
IPO Date Jun 27, 2017
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Sir Marc Feldmann Ph.D.

Contact Details

Address:
Building 4
Palo Alto, California
United States
Website https://180lifesciences.com

Stock Details

Ticker Symbol ATNF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690080
CUSIP Number 68236V104
ISIN Number US68236V3024
Employer ID 81-3832378
SIC Code 2834

Key Executives

Name Position
Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder & Director
Jason Assad Director of IR
Prof. Jagdeep Nanchahal M.D., Ph.D. Co-Founder & Chairman of Clinical Advisory Board
Sir Marc Feldmann Ph.D. Co-Founder

Latest SEC Filings

Date Type Title
Jan 10, 2025 SCHEDULE 13D Filing
Jan 10, 2025 D Filing
Jan 03, 2025 SCHEDULE 13G Filing
Jan 02, 2025 8-K/A [Amend] Current Report
Dec 31, 2024 8-K Current Report
Dec 31, 2024 3 Filing
Dec 30, 2024 8-K Current Report
Dec 30, 2024 424B5 Filing
Dec 23, 2024 S-1/A [Amend] Filing
Dec 20, 2024 S-1/A [Amend] Filing